Skip to main content

Table 2 Dose-volume and follow-up parameters for robotic stereotactic ablative body radiotherapy

From: Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function

Case

GTV (cm3)

PTV (cm3)

Margin (mm)

Dose (Gy)

PTV coverage (%)

nCI

Follow-up (month)

Local control

#1

8.2

17.9

4

1 × 24

97.8

1.07

54

SD

#2

20.4

31.0

3

1 × 25

97.8

1.06

23

PR

#3

13.5

17.0

13.5

17.0

0

0

1 × 24

1 × 24

96.8

98.5

1.13

1.13

47

CR

PR

#4

14.3

24.6

3

1 × 25

99.9

1.06

33

SD

#5

108.4

190.3

5

3 × 12

92.0

1.23

25

SD

#6

13.2

22.7

3

1 × 25

99.5

1.13

15

SD

#7

9.2

17.4

3

3 × 12

98.3

1.14

32

SD

#8

45.5

88.4

5

3 × 12

86.0

1.40

30

PD

#9

44.2

66.2

3

3 × 12

98.7

1.21

23

PR

#10

1.3

9.0

2.3

3.8

21.4

5.6

3

4

3

1 × 25

3 × 12

1 × 25

99.7

82.0

98.4

1.09

1.50

1.20

16

CR

PR

CR

  1. GTV Gross tumor volume, PTV planning target volume, nCI new conformity index, SD stable disease, PR partial remission, CR complete remission, PD progressive disease